Dutasteride for an Enlarged Prostate: Benefits, Side Effects and When Surgery May Be Better

Benign prostatic hyperplasia—usually called BPH or benign prostate enlargement—is a common cause of urinary symptoms as men get older.

An enlarged prostate can compress the urethra and interfere with bladder emptying, causing symptoms such as:

A slow or intermittent urinary stream
Difficulty starting urination
Straining to urinate
A feeling that the bladder has not emptied
Urinary frequency or urgency
Waking repeatedly at night to urinate
Dribbling after urination
Episodes of urinary retention

Duodart® combines two established BPH medicines in a single daily capsule. One component relaxes the prostate relatively quickly, while the other gradually reduces its size and lowers the long-term risk of urinary retention and prostate surgery.

Duodart can be very effective in appropriately selected men, but it is not the right treatment for every urinary symptom or every prostate.

What does Dutasteride contain?

Each Duodart capsule contains:

Dutasteride 0.5 mg
Tamsulosin hydrochloride 0.4 mg

These medicines work in different but complementary ways.

Tamsulosin: relaxing the prostate

Tamsulosin is an alpha-1 adrenergic receptor blocker. It relaxes smooth muscle within the prostate and bladder neck, reducing resistance to urinary flow.

It may improve:

Urinary stream
Hesitancy
Straining
Bladder emptying
Some frequency and urgency symptoms

Improvement may begin within days, although the full response can take several weeks.

Tamsulosin improves urinary symptoms but does not substantially reduce prostate size or prevent long-term prostate growth.

Dutasteride: gradually shrinking the prostate

Dutasteride is a 5-alpha-reductase inhibitor—5-ARI. It blocks both type 1 and type 2 forms of the enzyme that converts testosterone into dihydrotestosterone—DHT.

DHT is an important driver of prostate growth. Reducing DHT gradually causes susceptible prostate tissue to shrink.

According to the European Association of Urology, 5-ARIs can:

Reduce prostate volume by approximately 18–28%
Improve urinary symptom scores by approximately 15–30%
Reduce PSA by approximately 50% after six to twelve months
Reduce the long-term risk of acute urinary retention
Reduce the likelihood of requiring BPH surgery

The dutasteride component works slowly. A meaningful benefit may take three to six months, with further improvement occurring over several years.

Who may benefit from Duodart?

Duodart is most appropriate for men with moderate-to-severe urinary symptoms caused by an enlarged prostate who also have an increased risk of BPH progression.

It may be considered when there is:

A prostate volume of approximately 40 mL or greater
A clearly enlarged prostate on examination or ultrasound
An elevated PSA consistent with benign prostate enlargement
A reduced urinary flow rate
An increased post-void residual urine volume
Increasing symptoms despite alpha-blocker treatment
A risk of future urinary retention
A desire to reduce the likelihood of BPH-related surgery
A need for both relatively rapid symptom relief and long-term reduction in prostate size

Some men with prostates between 30 and 40 mL may also benefit, depending on their PSA, symptoms, urinary flow and other risk factors.

Combination treatment is generally intended for long-term use rather than a short trial lasting only a few weeks.

Who may not benefit?

Duodart is less likely to help when:

The prostate is small
Symptoms are primarily caused by an overactive bladder
There is poor bladder-muscle contraction
A urethral stricture is present
Prostate or bladder cancer is causing the obstruction
A bladder stone is responsible for the symptoms
Neurological bladder dysfunction is present
Symptoms are mild and not troublesome

A large prostate and severe symptoms do not always occur together. Some men with a very large prostate urinate reasonably well, while others with a small prostate have significant obstruction from a tight bladder neck, urethral narrowing or abnormal prostate shape.

This is why treatment should be based on an assessment rather than prostate size alone.

What assessment is recommended before starting Duodart?

Depending on the patient, assessment may include:

A detailed urinary and medication history
International Prostate Symptom Score—IPSS
Physical examination
Digital rectal examination
Urine testing
PSA testing
Kidney-function blood tests
Urinary flow-rate measurement
Ultrasound measurement of prostate size
Post-void residual urine measurement
A bladder diary when frequency or nocturia is prominent
Cystoscopy or urodynamic testing in selected patients

Prostate cancer and other important causes of urinary obstruction should be considered before symptoms are attributed to BPH.

How is Duodart taken?

The usual dose is one capsule once daily, taken approximately 30 minutes after the same meal each day.

The capsule should be swallowed whole. It should not be opened, crushed or chewed because its contents may irritate the mouth and throat.

Taking the capsule consistently after the same meal helps maintain predictable absorption of tamsulosin.

If treatment is stopped, urinary symptoms and prostate growth may gradually return. Duodart should not be stopped or restarted without discussing this with the prescribing doctor.

What benefits can be expected?

Tamsulosin provides the earlier benefit by relaxing the prostate and bladder neck. Dutasteride provides the slower, longer-term benefit by reducing prostate volume and the risk of progression.

In long-term clinical studies, dutasteride plus tamsulosin produced greater improvement in urinary symptoms and urinary flow than either medicine alone in appropriately selected men.

The EAU reports that, compared with tamsulosin alone at four years, combination treatment reduced the relative risk of:

Acute urinary retention by approximately 68%
BPH-related surgery by approximately 71%
Symptom deterioration by approximately 41%

These are relative reductions from clinical-trial populations. The individual absolute benefit depends on the patient’s original risk, prostate size, PSA and degree of obstruction.

Duodart controls BPH; it does not permanently cure it.

Common side effects

Because Duodart contains two medicines, it can cause side effects associated with either component.

Ejaculatory changes

Tamsulosin can interfere with ejaculation. Patients may notice:

Reduced semen volume
Dry ejaculation
Failure to ejaculate
Semen passing backwards into the bladder—retrograde ejaculation

This is usually harmless but can affect sexual satisfaction and fertility.

Combination treatment has a higher risk of ejaculatory dysfunction than either an alpha blocker or 5-ARI used alone.

Reduced sexual desire

Dutasteride reduces DHT and may cause a decrease in libido. The effect may be mild for some men but troubling for others.

Erectile dysfunction

Difficulty achieving or maintaining an erection can occur. BPH itself, increasing age, vascular disease, diabetes and other medications can also contribute, so the cause is not always straightforward.

Breast changes

Dutasteride can occasionally cause:

Breast tenderness
Nipple sensitivity
Breast enlargement—gynaecomastia

A breast lump, nipple discharge or persistent one-sided change should be assessed promptly rather than assumed to be a medication effect.

Dizziness and low blood pressure

Tamsulosin may lower blood pressure, particularly when standing. This can cause:

Dizziness
Light-headedness
Weakness
Fainting
An increased risk of falling

Extra care is needed when treatment begins, after a dose change or when Duodart is combined with other blood-pressure-lowering medicines.

Other possible side effects

Other reported effects include:

Headache
Tiredness
Palpitations
Nasal congestion
Gastrointestinal discomfort
Skin rash or itching
Testicular discomfort or swelling
Mood changes or depression
Reduced fertility or changes in semen quality

Semen-volume and sperm changes do not necessarily cause infertility, but men planning a pregnancy should discuss this before treatment.

Rare but important reactions

Urgent medical assistance is required for:

Swelling of the face, tongue or throat
Difficulty breathing
A severe allergic reaction
Fainting
A painful erection lasting several hours—priapism
Severe blistering or peeling skin
Marked depression or suicidal thoughts

These reactions are uncommon but require prompt assessment.

Duodart and cataract surgery

Tamsulosin is associated with intraoperative floppy iris syndrome, which can make cataract or glaucoma surgery more difficult.

Patients should tell their ophthalmologist if they:

Currently take Duodart
Previously took Duodart
Previously used another medicine containing tamsulosin

Stopping tamsulosin shortly before surgery may not completely remove this risk. The decision should be made between the ophthalmologist and prescribing doctor rather than by the patient alone.

Contraindications and important precautions

Duodart should not be used in:

Women
Children or adolescents
Anyone allergic to dutasteride, tamsulosin, another 5-ARI or a capsule ingredient
Patients with a history of significant postural or orthostatic hypotension
Patients with severe liver impairment

Additional caution is required in men with:

Recurrent dizziness or falls
Significant cardiovascular disease
Liver disease
Severe kidney impairment
Planned cataract or glaucoma surgery
A history of depression or major mood disturbance
Suspected prostate cancer
Severe urinary retention
A very high post-void residual urine volume
Other medicines that substantially lower blood pressure

Duodart changes the interpretation of PSA

Dutasteride generally lowers PSA by approximately 50% after six to twelve months.

This does not mean that prostate cancer risk has disappeared. A new PSA baseline should be established after treatment begins, and subsequent results must be interpreted in the context of dutasteride use.

A confirmed rise from the lowest PSA reached while taking Duodart may require investigation—even when the result remains within the laboratory’s usual “normal” range.

Patients should tell any doctor ordering or interpreting a PSA test that they are taking dutasteride.

PSA monitoring and appropriate prostate cancer assessment should continue while using Duodart.

What is “post-finasteride syndrome”?

“Post-finasteride syndrome” is a term used to describe persistent symptoms reported by some patients during or after stopping finasteride.

Reported symptoms have included:

Reduced libido
Erectile dysfunction
Altered genital sensation
Ejaculatory or orgasmic changes
Fatigue
Poor concentration or “brain fog”
Anxiety
Depressed mood
Sleep disturbance

The existence, frequency, biological mechanism and diagnostic criteria of post-finasteride syndrome remain debated. Some patients report very real and persistent symptoms, but current research has not established a reliable way to predict who may be affected or to prove that every reported symptom is directly caused by the medicine.

It should therefore neither be presented as a guaranteed consequence nor dismissed when a patient reports persistent symptoms.

Is post-finasteride syndrome relevant to Duodart?

Duodart does not contain finasteride. It contains dutasteride.

However, finasteride and dutasteride belong to the same 5-ARI medicine class and both reduce DHT. Sexual side effects such as reduced libido, erectile dysfunction and ejaculatory changes are recognised with both medicines.

Dutasteride inhibits both type 1 and type 2 5-alpha-reductase and remains in the body much longer than finasteride. Its terminal half-life is approximately five weeks, so adverse effects may not disappear immediately after stopping treatment.

Persistent sexual symptoms have been reported after treatment with 5-ARIs, although the frequency and causal relationship remain uncertain.

A 2025 European Medicines Agency safety review found insufficient evidence to establish a causal association between dutasteride and suicidal thoughts. Nevertheless, because of a possible class effect, the EMA recommended precautionary information about mood changes for dutasteride products.

Patients taking Duodart should contact their doctor if they develop:

New or worsening sexual dysfunction
Persistent loss of libido
Depressed mood
Significant anxiety
Suicidal thoughts
Symptoms that continue after stopping treatment

Stopping Duodart suddenly may allow urinary obstruction to worsen, so medication changes should usually be supervised. Suicidal thoughts or severe psychological distress require urgent assistance.

Monitoring treatment

Patients should usually be reviewed after starting Duodart to assess:

Improvement in urinary symptoms
Dizziness or postural blood-pressure changes
Sexual and ejaculatory function
Mood changes
Urinary flow rate
Post-void residual urine
PSA response
Kidney function when clinically indicated

The tamsulosin component should produce an earlier response, while the dutasteride benefit is judged over several months.

A lack of rapid improvement does not necessarily mean dutasteride has failed. Conversely, ongoing severe symptoms should not automatically be managed by continuing the medication indefinitely without reassessment.

When should surgery be considered?

Medication is often the first treatment for uncomplicated BPH, but surgery should not be regarded merely as a last resort. For some patients it offers more reliable relief and prevents further bladder or kidney damage.

Surgery should be considered when there is:

Recurrent or persistent urinary retention
Dependence on a urinary catheter
Recurrent urinary tract infections caused by poor emptying
Bladder stones
Recurrent visible bleeding attributable to BPH
Overflow urinary incontinence
Progressive bladder diverticula associated with obstruction
Dilatation of the kidneys or ureters
Kidney impairment caused by bladder outlet obstruction
A very high or increasing residual urine volume
Persistent bothersome symptoms despite adequate medication
Intolerable medication side effects
A preference for a procedural solution rather than lifelong tablets
Poor urinary flow with objective evidence of significant obstruction

Earlier surgery may also be appropriate when obstruction is beginning to damage bladder function. Waiting until the bladder has become severely stretched or weak can reduce the improvement achievable after surgery.

When is Duodart unlikely to prevent surgery?

Surgery may still be needed when:

The prostate obstruction is mechanically severe
A large middle lobe acts like a ball valve at the bladder outlet
Urinary retention has already occurred repeatedly
Bladder stones or recurrent infections are present
Residual urine continues to increase
Kidney function or upper urinary tract drainage is affected
Symptoms remain troublesome after an adequate trial
The bladder has become poorly contractile
Side effects make long-term treatment unacceptable

Duodart can reduce future risk; it cannot reliably reverse every established complication of obstruction.

What surgical options are available?

The appropriate procedure depends on prostate size, prostate shape, bleeding risk, bladder function, general health and the importance of preserving ejaculation.

Options may include:

Transurethral resection of the prostate—TURP
GreenLight laser prostate vaporisation
Holmium laser enucleation—HoLEP
Rezūm water-vapour therapy
UroLift
Temporary implantable nitinol device—iTind
Robotic or open simple prostatectomy for very large glands
Other enucleation or minimally invasive techniques

Some minimally invasive treatments are best suited to selected prostate sizes and shapes. Not every option provides the same durability, improvement in urinary flow or preservation of ejaculation.

The bottom line

Duodart combines the relatively quick muscle-relaxing effect of tamsulosin with the slower prostate-shrinking and progression-reducing effect of dutasteride.

It is most useful for men with moderate-to-severe urinary symptoms, a genuinely enlarged prostate and a meaningful risk of future urinary retention or surgery.

Sexual and ejaculatory side effects, dizziness, breast changes and possible mood effects should be discussed before treatment. Duodart also lowers PSA, so ongoing prostate cancer surveillance must be interpreted differently.

The term “post-finasteride syndrome” remains scientifically debated. Duodart does not contain finasteride, but dutasteride acts on the same hormonal pathway, and persistent symptoms reported by a patient deserve careful assessment.

Medication should not be continued indefinitely when symptoms remain severe, complications develop or bladder and kidney function are threatened. In those circumstances, timely prostate surgery may be safer and more effective than simply adding another tablet.

This article provides general information and does not replace personalised medical advice. Patients should not start, stop or alter Duodart without consulting their treating doctor.

So, if you are having difficulty with your lower urinary tract symptoms and you wish to remain conservative in your management and not to fussed about your erectile function and libido, come see your local Brisbane urologist, dr Jo Schoeman, to discuss further options